The study analysed
that the therapeutics pipeline comprises of approximately 29 drug candidates in
different stages of development. Myelofibrosis is a rare disorder in which excessive scar tissue gets formed in
the bone marrow that impairs its ability to produce red blood cells. However,
it is believed by researchers that myelofibrosis occurs due to the presence of
abnormal red blood stem cells in the bone marrow. The abnormal blood stem cells
produce mature cells that grow quickly and form scar tissue which leads to
chronic inflammation.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=myelofibrosis-therapeutics-pipeline-analysis
